m+Medelevator.RU
← Поиск публикаций
EFSA journal. European Food Safety Authority · 2026

Use of conversion factors for the setting of MRLs of prothioconazole.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

European Food Safety Authority (EFSA), Bellisai Giulia, Bernasconi Giovanni, Cabrera Luis Carrasco, Castellan Irene, Del Aguila Monica, Ferreira Lucien, Greco Luna, Leuschner Renata, Mioč Andrea, Nave Stefanie, Reich Hermine, Ruocco Silvia, Scarlato Alessia Pia, Szot Marta, Theobald Anne, Tiramani Manuela, Verani Alessia, Zioga Elena

Аннотация

In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer AG Crop Science Division submitted a request to the competent national authority in France to use conversion factors for the setting of maximum residue levels (MRLs) for prothioconazole. The applicant did not propose modification of the existing EU MRLs for prothioconazole, as currently set in Regulation (EU) 2024/1318. The data provided in the previous EFSA outputs and submitted under the present assessment were sufficient to derive crop-specific conversion factors for all crops under consideration, except for pulses, head cabbage and flowering brassica. For onions and shallots, the submitted data are considered to support a less conservative good agricultural practice (GAP). Moreover, the data submitted were found sufficient to confirm tentative MRLs for prothioconazole in leek, Brussels sprouts, barley, oat, wheat, rye grain and in commodities of animal origin. An updated EU livestock dietary burden indicates that lower EU MRLs would be sufficient in liver, kidney and edible offal of ruminants, swine and poultry and in the fat of ruminants and swine. EFSA concluded that the existing EU uses of prothioconazole will not result in a consumer exposure exceeding the toxicological reference values and therefore are unlikely to pose a risk to consumers' health. All conclusions derived under the present assessment are considered provisional and might need to be reconsidered once the decision on the renewal of approval of prothioconazole (and related new endpoints) is implemented by the European Commission.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты